Who are we?
Expertise & Partnership for Your Health
In the dynamic and constantly evolving environment of the pharmaceutical market within the Eurasian Economic Union (EAEU), Adelvas represents a new, yet exceptionally experienced, participant. Founded in 2023, our company is built upon a foundation of decades of practical experience held by its founders – recognized professionals in the EAEU pharmaceutical industry, whose cumulative tenure in senior management positions at leading global companies exceeds 20 years.
Deep Understanding of the EAEU Market (Republic of Armenia, Russian Federation, Republic of Kazakhstan, Republic of Belarus, Kyrgyz Republic)
At Adelvas, we possess a thorough understanding of the complexities and opportunities inherent in the EAEU pharmaceutical market. Our experience covers all aspects of this market’s functioning – from navigating the ongoing harmonization of regulatory requirements to considering the persistent national specifics in pricing, advertising, and public procurement within each member state.
Expertise in Marketing, Sales, Distribution, and Registration
Success in the EAEU market requires more than just regulatory compliance. Adelvas possesses a comprehensive understanding of the most effective ways and means of selling pharmaceutical products in the region. We know how to establish optimal distribution channels, develop effective marketing strategies, and implement advertising campaigns that not only reach the target audience but also strictly comply with the specific national regulations governing the advertising of medicinal products in the EAEU countries. Our approach is grounded in in-depth market analysis and many years of experience in launching products and maximizing their commercial potential.
Legal and Regulatory Competence
The Adelvas team possesses proven legal competence and deep knowledge of the regulatory environment across all EAEU countries. We provide full support at all stages – from the preparation and submission of the registration dossier and navigating Mutual Recognition Procedures (MRP) or Decentralized Procedures (DCP) to ensuring compliance with EAEU Good Manufacturing Practice (GMP) requirements and Pharmacovigilance (PV). Our experience allows for the minimization of risks and acceleration of the authorization process.
Commitment to Quality and Openness to Dialogue
For Adelvas, product quality is an absolute priority. We understand that behind every product lies the health and well-being of patients, and therefore, we apply the strictest control standards at all stages of our activities, ensuring compliance with international norms and EAEU requirements. It is important for us not only to supply high-quality products but also to continuously improve. We are always open to feedback and value any comments and suggestions regarding our products. Your contribution helps us become better and ensures that our products meet the highest expectations.